GlassScriptPhysician profile
Aaron Newey Weaver
NPI 1750594222
$14,062.44
in general payments reported to CMS, 2019-2025
42 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,875 · 2020: $1,396 · 2021: $1,285 · 2022: $1,848 · 2023: $2,489 · 2024: $1,775 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750 · Travel and Lodging: $866 · Education: $43.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,750.18 |
| Travel and Lodging | $865.60 |
| Education | $43.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,913.90 | 2019-2023 | Mitraclip |
| Pfizer INC. | $1,641.98 | 2019-2025 | |
| Amgen INC. | $1,455.97 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,071.65 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,010.38 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $961.46 | 2019-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $879.30 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $663.19 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $425.34 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $415.79 | 2019-2024 | Watchman Flx, Synergy, Watchman Access System |
| Amarin Pharma, INC. | $380.52 | 2019-2022 | |
| United Therapeutics Corporation | $327.67 | 2019-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $291.72 | 2019-2023 | Farxiga |
| W. L. Gore & Associates, INC. | $276.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.13 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $121.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $118.88 | 2019 | |
| Chiesi USA, INC. | $115.72 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $111.80 | 2024 | Arcalyst |
| Baxter Healthcare | $84.08 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $65.77 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.12 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $50.01 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $49.84 | 2023-2024 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $39.49 | 2024 | Inpefa |
| Heartflow, INC. | $37.89 | 2022-2025 | |
| Esperion Therapeutics, INC. | $33.57 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $31.89 | 2025 | Wegovy |
| Cordis US Corp. | $30.98 | 2024 | Mynx Venous Vcd |
| Kiniksa Pharmaceuticals, LTD. | $23.93 | 2023 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $21.33 | 2019 | |
| Abiomed | $19.96 | 2024 | Impella |
| Abbvie INC. | $19.95 | 2023 | Vraylar |
| Cvrx, INC. | $19.07 | 2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $18.45 | 2025 | Injectafer |
| Akcea Therapeutics, INC. | $18.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.19 | 2021 | |
| Inspire Medical Systems, INC. | $15.38 | 2025 | Inspire |
| Livanova USA, INC. | $14.76 | 2021 | |
| Analog Devices INC. | $14.02 | 2024 | Sensinel Cpm Wearable |
| Sanofi-Aventis U.S. LLC | $11.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.